Hims & Hers Health faces a federal lawsuit alleging it shared consumers' sensitive health information with third-party advertising platforms, charged customers before they spoke with a medical provider, and made it difficult to cancel subscriptions.
The agency alleges the telehealth company shared sensitive health data with Meta and Snap while deceiving users about charges and cancellations
Cheng Xin / Getty Images
Hims & Hers Health faces a federal lawsuit alleging it shared consumers' sensitive health information with third-party advertising platforms, charged customers before they spoke with a medical provider, and made it difficult to cancel subscriptions.
The Federal Trade Commission, joined by Utah and Los Angeles County, filed the complaint Wednesday in U.S. District Court for the Northern District of California. The agency alleges Hims & Hers shared customer health data with Meta $META Platforms and Snap $SNAP through customer lists and tracking technologies embedded on its website, despite promising to protect user privacy.
The FTC also alleges that the company typically bills customers for prescription treatments once they submit an intake form, meaning payment is collected before a provider ever weighs in — a practice the agency says contradicts representations Hims & Hers made to consumers. "I was told that I would be able to speak with a doctor in a few days and that nothing would be charged to my card that day. Him's & Her's charged me immediately," one consumer complained, according to the FTC.
The agency further alleges the company made cancellations difficult. Before 2023, most consumers could only cancel by contacting customer service by phone, email, or chat. After introducing an online cancellation option, the company buried the cancellation button behind multiple navigation steps, the FTC alleges.
"The FTC will not hesitate to act on behalf of consumers deprived of their ability to choose which products they want and whether to keep their most sensitive health information private," Christopher Mufarrige, director of the FTC's Bureau of Consumer Protection, said in a statement.
The FTC alleges violations of the FTC Act and the Restore Online Shoppers' Confidence Act. Utah alleges violations of the Utah Consumer Sales Practices Act, and California alleges violations of the state's false advertising and unfair competition laws. The Commission vote to file was 2-0.
Hims & Hers rejected the allegations, saying the lawsuit "disregards substantial evidence" provided during the FTC's nearly three-year investigation and "contorts the law to try to manufacture claims." The company expressed confidence in its position and said it intended to fight the case.
Hims & Hers stock fell around 12% on the news.
The lawsuit comes as the San Francisco-based company has been navigating a broader transition in its business. Hims & Hers swung to a net loss of $92.1 million in the first quarter of 2026 as it shifted away from compounded weight loss drugs toward branded GLP-1 medications, a move that weighed on margins and earnings even as revenue rose 4% year over year to $608.1 million.
According to CNBC, the FTC opened its inquiry in October 2023 and by April had relayed its conclusions to the company, at which point settlement talks got underway. In May, the company recorded a $15 million probable-loss accrual tied to the matter and put forward a settlement proposal that stopped short of any admission of wrongdoing, though the FTC ultimately moved ahead with Wednesday's suit.
Join 500,000+ readers who start their day with Quartz.
By subscribing, you agree to our Terms of Service and Privacy Policy.